DE1359854U
(enExample )
CA2350246C
(en )
2010-04-27
Controlled delivery of active agents
US5897878A
(en )
1999-04-27
Method for administering steroid
US4915953A
(en )
1990-04-10
Dosage form for delivering acetaminophen or phenylpropanolamine
US5830502A
(en )
1998-11-03
Injection-molded dosage form
AU619454B2
(en )
1992-01-30
Dispenser comprising displaceable matrix with solid state properties
EP1539144B1
(en )
2014-12-24
Multistage formulation containing a biguanide and a thiazolidinedione derivative
US5326571A
(en )
1994-07-05
Dosage forms comprising polymers comprising different molecular weights
US4940465A
(en )
1990-07-10
Dispenser comprising displaceable matrix with solid state properties
IE892845A1
(en )
1991-03-13
Controlled-release oral dosage forms comprising different cellulose ethers
US20100316708A1
(en )
2010-12-16
Novel Pharmaceutical Formulation Containing A Biguanide and a Thiazolidinedione Derivative
US4732915A
(en )
1988-03-22
Process for increasing solubility of drug
US5266332A
(en )
1993-11-30
Method for administering anti-Parkinson drug
WO2006044077A2
(en )
2006-04-27
Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
US20050287214A1
(en )
2005-12-29
Squeeze controlled oral dosage form
IL297368A
(en )
2022-12-01
Long-acting peptide tyrosine kinase (pyy) analogs and methods of use
EP2848245A1
(en )
2015-03-18
Bosentan controlled release oral preparation
KR101010325B1
(ko )
2011-01-25
텔미사르탄 및 히드로클로로티아지드를 함유하는 약제학적 조성물
DE1460624U
(enExample )
DE1401201U
(enExample )
CA1336070C
(en )
1995-06-27
Controlled release dosage form comprising different cellulose ethers
DE1438762U
(enExample )
DE1455910U
(enExample )
AU731358B2
(en )
2001-03-29
Injection-molded dosage form
DE1288387U
(enExample )